PAX5 Antibody, FITC conjugated

1. The functional role of PAX5-ELN as a potent oncoprotein in B-cell acute lymphoblastic leukemia development. PMID: 30257940
2. PAX5 gene methylation can predict poor survival outcomes and cisplatin sensitivity in esophageal squamous cell carcinomaand could be a useful diagnostic tool for cancer therapy selection PMID: 29099287
3. Study demonstrated that Pax-5 regulates numerous miRNAs including miR-215 which is aberrantly under-expressed in breast cancer tumors. Pax-5 was found to inhibit aggressive features of breast cancer cells in a miR-215- dependent manner. PMID: 30194145
4. The correlation between Pax5 deletion and patients survival in Iranian children with precursor B-cell acute lymphocytic leukemia hs been reported. PMID: 28886309
5. this study demonstrates a role for the AHR in regulating human B cell development, and it suggests that transcriptional alterations of PAX5 by the AHR are involved in the underlying mechanism PMID: 28978690
6. These findings suggested that pax5 is critically important for the proliferation and survival of pre-B cells. PMID: 27016671
7. a mechanism of transcriptional regulation mediated by p27, Pax5, and PCAF PMID: 28158851
8. Data show that paired box gene 5 (B-cell lineage specific activator) protein (Pax-5) induces E-cadherin expression in breast cancer cells. PMID: 28076843
9. PAX5-KIDINS220 fusion is associated with Philadelphia-like acute lymphoblastic leukemia. PMID: 27870151
10. this study shows that Pax5 expression is lower in antibody-secreting cells than in naive B cells or plasmablasts PMID: 27525369
11. The histological observations suggested that the patients represent diverse cases of NHL like mature B-cell type, mature T-cell type and high grade diffuse B-cell type NHL. The findings indicate that patients with NHL may also be analyzed for status of PAX5, CD19 and ZAP70, and their transcriptional and post-translational variants for the differential diagnosis of NHL and therapy. PMID: 27748274
12. B cell receptor signaling component, SYK, caused PAX5 tyrosine phosphorylation in vitro and in cells. Transcriptional repression on the BLIMP1 promoter by PAX5 was attenuated by this phosphorylation. PMID: 27181361
13. PAX5 haploinsufficiency promotes tumorigenesis and may be related to genomic instability, immune tolerance, and tumor pathways PMID: 28316978
14. FISH studies showed false-negative results in 10, 40, and 28% of the samples tested for the IKZF1,PAX5, and CDKN2A/B gene deletions, respectively. The PAX5 and IKZF1 abnormalities are highly specific to B-ALL and can be used as diagnostic markers PMID: 28214896
15. The Correlation between GATA5, WT1 and PAX5 methylation and clinical/histological parameters is suggestive of applicability of these markers in non-invasive (epi)genetic testing in hepatocellular carcinoma (HCC). PMID: 27171388
16. we identified gene promoter methylation signatures (WT1, MSH6, GATA5 and PAX5) that are strongly correlated to, and can have a predictive value for the clinical outcome of oral squamous cell carcinoma patients PMID: 27491556
17. PAX5 expression is infrequent (27.27%) in Olfactory neuroblastoma; however, if present it can be associated with a very aggressive clinical course. PMID: 27543867
18. Report Pax5 expression is common in combined Merkel cell carcinoma. PMID: 27322785
19. PAX5 was found to be an epigenetically inactivated tumor suppressor that inhibited non-small-cell lung proliferation and metastasis, through down-regulating the beta-catenin pathway and up-regulating GADD45G expression. PMID: 26843424
20. Our findings suggest that this mutation in a single allele of the PAX5 gene is not sufficient to cause disease, and it is possible that other alleles are also involved in the onset of B-ALL. PMID: 26782422
21. PAX5 methylated imprint margins may signify recurrence in head and neck squamous cell carcinoma PMID: 26304463
22. Authors demonstrate leukemogenicity of PAX5-PML by introducing it into normal mouse pro-B cells; B-cell linker protein (Blnk) is repressed by PAX5-PML in leukemia cells; enforced expression of Blnk increases survival despite introduction of PAX5-PML. PMID: 26703467
23. PAX5 deletion is an independent risk factor for DFS in B-ALL children. PMID: 27097569
24. Differential PAX5 levels promote malignant B-cell infiltration, progression and drug resistance, and predict a poor prognosis in mantle cell lymphoma patients independent of CCND1. PMID: 26073757
25. This is the first reported case of a novel complex variant translocation of t(11;14)(q13;q32) and t(9;14)(p13;q32)in PAX5-positive plasma cell myeloma. PMID: 25633778
26. Cells from PAX5 translocated patients show LCK up-regulation and over-activation, as well as STAT5 hyper-phosphorylation, compared to PAX5 wt and PAX5 deleted cases. PMID: 25595912
27. Increased hypermethylation of PAX5 is associated with Triple negative breast cancer. PMID: 25684485
28. PAX5 gene translocation is associated with B-cell precursor acute lymphoblastic leukemia. PMID: 25304615
29. These findings indicated that the methylated CpG -236 of PAX5 promoter has the potential applicability for clinical evaluation the prognosis of gastric cancer PMID: 25277182
30. We report the immunoreactivity expression patterns of three PAX genes (PAX2, PAX5 and PAX8) in poorly differentiated small round cell tumors of childhood for possible useful diagnostic applications. PMID: 24897005
31. PAX5-JAK2 simultaneously deregulates the PAX5 downstream transcriptional program and activates the Janus kinase-STAT signaling cascade and thus, by interfering with these two important pathways, may promote leukemogenesis. PMID: 25515960
32. a novel link wherein placenta growth factor-mediated downregulation of paired box protein 5 attenuates miR-648 expression leading to increased endothelin-1 levels that are known to induce Pulmonary hypertension in sickle cell anemia PMID: 25403488
33. Study identified PAX5 as a novel EBER2-interacting protein, prompted by the observation that this transcription factor and the viral noncoding RNA co-localize at the tandem repeats, interaction appears to be indirect, based on the negative results of electrophoretic mobility shift assays and UV crosslinking experiments. PMID: 25662012
34. Data show that leukemia-associated PAX5 fusion proteins share some dominating characteristics such as nuclear localization and DNA binding but also show distinctive features. PMID: 24435167
35. MCOLN2 is transcriptionally activated by PAX5 and has roles in B cell development and function PMID: 25445271
36. Downregulation of PAX6 in SS patients was highly associated with ocular surface damage and largely dependent on the level of inflammation. PMID: 25228544
37. Data indicate that somatic PAX5 mutation may be a rare event in multiple myelomas and DLBCL, and may not contribute to development of these malignancies of Korean patients. PMID: 23737402
38. Low PAX5 expression is associated with atypical non-Langerhans cell histiocytic tumor post acute lymphoblastic leukemia. PMID: 24569775
39. data clearly demonstrate that the expression of PAX5 with or without global DNA demethylation/histone acetylation is not sufficient to induce a B-cell phenotype in HRS cells. PMID: 23842424
40. The frequency of PAX5 gene alterations in B cell acute lymphoblastic leukemia harboring 9p abnormalities was 52%. PMID: 24078568
41. data extend the role of PAX5 alterations in the pathogenesis of pre-B cell ALL and implicate PAX5 in a new syndrome of susceptibility to pre-B cell neoplasia PMID: 24013638
42. Deregulated MAP kinase signaling in t(8;21) Acute myeloid leukemia abrogates the association of polycomb complexes to PAX5 and leads to aberrant gene activation. PMID: 23616623
43. The B-cell-specific transcription factor and master regulator Pax5 promotes Epstein-Barr virus latency by negatively regulating the viral immediate early protein BZLF1. PMID: 23678172
44. The purpose of this study was to evaluate the expression patterns of B-cell specific activator protein (BSAP)/PAX5 and PAX8 in a wide variety of B-cell and T-cell neoplasms PMID: 23163626
45. Our study confirms that PAX5 and TdT expression can be expressed in a high percentage of Merkel cell carcinomas and so when positive are not diagnostic of lymphoblastic leukemia/lymphoma. PMID: 23329999
46. first, PAX5/ETV6 determines a PAX5 haploinsufficiency setting; second, the fusion protein could be responsible for the B-cell development block PMID: 23090680
47. PAX5 emerges as one of the major SOX11 direct targets. SOX11 silencing downregulates PAX5. PMID: 23321250
48. reduced expression of huPax5 during the induction of early lymphoid progenitors to B-lineage-committed cells can fix this cellular development at a stage that has previously been seen during embryonic development PMID: 22927250
49. Pax-5 plays a key role in phenotypic transitioning during metastasis through the regulation of FAK1 activity. (Review) PMID: 21707507
50. PAX5 is a novel functional tumor suppressor in gastric carcinogenesis PMID: 22105368

Show More

Hide All

HGNC: 8619

OMIM: 167414

KEGG: hsa:5079

STRING: 9606.ENSP00000350844

UniGene: Hs.654464